Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES23)
Immunoconjugate targeting of solid tumors has not been routinely successful because the endo-thelial cells of blood vessels act as a physical barrier against the transport of macromolecules, such as antibodies. In the present study, we attempted to achieve tumor vascular targeting with an anti-tumor...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of cancer research (Gann) 2000-12, Vol.91 (12), p.1319-1325 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1325 |
|---|---|
| container_issue | 12 |
| container_start_page | 1319 |
| container_title | Japanese journal of cancer research (Gann) |
| container_volume | 91 |
| creator | WAKAI, Yukiko MATSUI, Junji TSUTSUMI, Yasuo NAKAGAWA, Shinsaku OHSUGI, Yoshiyuki MAYUMI, Tadanori KOIZUMI, Keiichi TSUNODA, Shin-Ichi MAKIMOTO, Hiroo OHIZUMI, Iwao TANIGUCHI, Kenji KAIHO, Shin-Ihi SAITO, Hiroyuki UTOGUCHI, Naoki |
| description | Immunoconjugate targeting of solid tumors has not been routinely successful because the endo-thelial cells of blood vessels act as a physical barrier against the transport of macromolecules, such as antibodies. In the present study, we attempted to achieve tumor vascular targeting with an anti-tumor tissue endothelium-specific monoclonal antibody (TES-23). TES-23, an IgG1 monoclonal antibody raised against rat KMT-17 fibrosarcoma-derived endothelial cells, was covalently conjugated with neocarzinostatin (NCS) in a previous study. The TES-23-NCS conjugate induced tumor hemorrhagic necrosis, and showed marked anti-tumor effects against rat KMT-17 fibrosarcoma. This result prompted us to investigate whether this approach would be applicable to various other types of solid tumors. One hour after injection of (125)I-labeled TES-23 into BALB / c mice bearing Meth-A fibrosarcoma and Colon 26 adenocarcinoma, the tumor accumulation of TES-23 was greater than that of the control IgG. In the present study, we report the anti-tumor effects of this monoclonal antibody in mice bearing Meth-A fibrosarcoma. Mice treated with the immunoconjugate showed improved survival with no side effects. This result indicates that common antigens may be found in different kinds of tumor endothelial cells, and that TES-23 might recognize these antigens. |
| doi_str_mv | 10.1111/j.1349-7006.2000.tb00920.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72541090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72541090</sourcerecordid><originalsourceid>FETCH-LOGICAL-j259t-3fccb9892b33ab04472e26c12c429114af67e9b8c853acc7cad64349667873413</originalsourceid><addsrcrecordid>eNo9kE1PwzAMhiMEgjH4C6gCCcGhxflo0hzRND6kSRwY5ypN05GpbUaTTuzfE2BgWfbBj1_ZL0KXGDIc426dYcpkKgB4RgAgCxWAJJB9HqAJLgRPGRf0EE1AYkhzyOEEnXq_BsACODlGJ1GFUEbJBLl50xgd7NYkWvXaDElQw8oE26-S0X9X1ccMNg1j5-LUej-aZKu8Hls1JKavXXg3rR271G-Mto3VSed6p1vXq_ZntXL1LrlZzl8JvT1DR41qvTnf9yl6e5gvZ0_p4uXxeXa_SNcklyGljdaVLCSpKFUVMCaIIVxjohmRGDPVcGFkVegip0proVXNWTSFc1EIyjCdoutf3c3gPkbjQ9lZr03bqt640ZeC5AyDhAhe7MGx6kxdbgbbqWFX_lkUgas9EH9WbTNEm6z_5-I1NB7xBeV4eBw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72541090</pqid></control><display><type>article</type><title>Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES23)</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>WAKAI, Yukiko ; MATSUI, Junji ; TSUTSUMI, Yasuo ; NAKAGAWA, Shinsaku ; OHSUGI, Yoshiyuki ; MAYUMI, Tadanori ; KOIZUMI, Keiichi ; TSUNODA, Shin-Ichi ; MAKIMOTO, Hiroo ; OHIZUMI, Iwao ; TANIGUCHI, Kenji ; KAIHO, Shin-Ihi ; SAITO, Hiroyuki ; UTOGUCHI, Naoki</creator><creatorcontrib>WAKAI, Yukiko ; MATSUI, Junji ; TSUTSUMI, Yasuo ; NAKAGAWA, Shinsaku ; OHSUGI, Yoshiyuki ; MAYUMI, Tadanori ; KOIZUMI, Keiichi ; TSUNODA, Shin-Ichi ; MAKIMOTO, Hiroo ; OHIZUMI, Iwao ; TANIGUCHI, Kenji ; KAIHO, Shin-Ihi ; SAITO, Hiroyuki ; UTOGUCHI, Naoki</creatorcontrib><description>Immunoconjugate targeting of solid tumors has not been routinely successful because the endo-thelial cells of blood vessels act as a physical barrier against the transport of macromolecules, such as antibodies. In the present study, we attempted to achieve tumor vascular targeting with an anti-tumor tissue endothelium-specific monoclonal antibody (TES-23). TES-23, an IgG1 monoclonal antibody raised against rat KMT-17 fibrosarcoma-derived endothelial cells, was covalently conjugated with neocarzinostatin (NCS) in a previous study. The TES-23-NCS conjugate induced tumor hemorrhagic necrosis, and showed marked anti-tumor effects against rat KMT-17 fibrosarcoma. This result prompted us to investigate whether this approach would be applicable to various other types of solid tumors. One hour after injection of (125)I-labeled TES-23 into BALB / c mice bearing Meth-A fibrosarcoma and Colon 26 adenocarcinoma, the tumor accumulation of TES-23 was greater than that of the control IgG. In the present study, we report the anti-tumor effects of this monoclonal antibody in mice bearing Meth-A fibrosarcoma. Mice treated with the immunoconjugate showed improved survival with no side effects. This result indicates that common antigens may be found in different kinds of tumor endothelial cells, and that TES-23 might recognize these antigens.</description><identifier>ISSN: 0910-5050</identifier><identifier>EISSN: 1876-4673</identifier><identifier>DOI: 10.1111/j.1349-7006.2000.tb00920.x</identifier><identifier>PMID: 11123432</identifier><identifier>CODEN: GANNA2</identifier><language>eng</language><publisher>Tokyo: Japanese Cancer Association</publisher><subject>Animals ; Antibodies, Monoclonal - pharmacokinetics ; Antibodies, Monoclonal - therapeutic use ; Antibody Specificity ; Antineoplastic agents ; Biological and medical sciences ; Body Weight ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Endothelium, Vascular - immunology ; Female ; Fibrosarcoma - blood supply ; Fibrosarcoma - drug therapy ; Fibrosarcoma - radiotherapy ; Hemorrhage ; Immunoglobulin G ; Iodine Radioisotopes - pharmacokinetics ; Iodine Radioisotopes - therapeutic use ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Necrosis ; Pharmacology. Drug treatments ; Radioimmunotherapy - methods ; Rats ; Tissue Distribution ; Zinostatin - pharmacokinetics ; Zinostatin - therapeutic use</subject><ispartof>Japanese journal of cancer research (Gann), 2000-12, Vol.91 (12), p.1319-1325</ispartof><rights>2001 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=911385$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11123432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WAKAI, Yukiko</creatorcontrib><creatorcontrib>MATSUI, Junji</creatorcontrib><creatorcontrib>TSUTSUMI, Yasuo</creatorcontrib><creatorcontrib>NAKAGAWA, Shinsaku</creatorcontrib><creatorcontrib>OHSUGI, Yoshiyuki</creatorcontrib><creatorcontrib>MAYUMI, Tadanori</creatorcontrib><creatorcontrib>KOIZUMI, Keiichi</creatorcontrib><creatorcontrib>TSUNODA, Shin-Ichi</creatorcontrib><creatorcontrib>MAKIMOTO, Hiroo</creatorcontrib><creatorcontrib>OHIZUMI, Iwao</creatorcontrib><creatorcontrib>TANIGUCHI, Kenji</creatorcontrib><creatorcontrib>KAIHO, Shin-Ihi</creatorcontrib><creatorcontrib>SAITO, Hiroyuki</creatorcontrib><creatorcontrib>UTOGUCHI, Naoki</creatorcontrib><title>Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES23)</title><title>Japanese journal of cancer research (Gann)</title><addtitle>Jpn J Cancer Res</addtitle><description>Immunoconjugate targeting of solid tumors has not been routinely successful because the endo-thelial cells of blood vessels act as a physical barrier against the transport of macromolecules, such as antibodies. In the present study, we attempted to achieve tumor vascular targeting with an anti-tumor tissue endothelium-specific monoclonal antibody (TES-23). TES-23, an IgG1 monoclonal antibody raised against rat KMT-17 fibrosarcoma-derived endothelial cells, was covalently conjugated with neocarzinostatin (NCS) in a previous study. The TES-23-NCS conjugate induced tumor hemorrhagic necrosis, and showed marked anti-tumor effects against rat KMT-17 fibrosarcoma. This result prompted us to investigate whether this approach would be applicable to various other types of solid tumors. One hour after injection of (125)I-labeled TES-23 into BALB / c mice bearing Meth-A fibrosarcoma and Colon 26 adenocarcinoma, the tumor accumulation of TES-23 was greater than that of the control IgG. In the present study, we report the anti-tumor effects of this monoclonal antibody in mice bearing Meth-A fibrosarcoma. Mice treated with the immunoconjugate showed improved survival with no side effects. This result indicates that common antigens may be found in different kinds of tumor endothelial cells, and that TES-23 might recognize these antigens.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibody Specificity</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Body Weight</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Endothelium, Vascular - immunology</subject><subject>Female</subject><subject>Fibrosarcoma - blood supply</subject><subject>Fibrosarcoma - drug therapy</subject><subject>Fibrosarcoma - radiotherapy</subject><subject>Hemorrhage</subject><subject>Immunoglobulin G</subject><subject>Iodine Radioisotopes - pharmacokinetics</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Necrosis</subject><subject>Pharmacology. Drug treatments</subject><subject>Radioimmunotherapy - methods</subject><subject>Rats</subject><subject>Tissue Distribution</subject><subject>Zinostatin - pharmacokinetics</subject><subject>Zinostatin - therapeutic use</subject><issn>0910-5050</issn><issn>1876-4673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1PwzAMhiMEgjH4C6gCCcGhxflo0hzRND6kSRwY5ypN05GpbUaTTuzfE2BgWfbBj1_ZL0KXGDIc426dYcpkKgB4RgAgCxWAJJB9HqAJLgRPGRf0EE1AYkhzyOEEnXq_BsACODlGJ1GFUEbJBLl50xgd7NYkWvXaDElQw8oE26-S0X9X1ccMNg1j5-LUej-aZKu8Hls1JKavXXg3rR271G-Mto3VSed6p1vXq_ZntXL1LrlZzl8JvT1DR41qvTnf9yl6e5gvZ0_p4uXxeXa_SNcklyGljdaVLCSpKFUVMCaIIVxjohmRGDPVcGFkVegip0proVXNWTSFc1EIyjCdoutf3c3gPkbjQ9lZr03bqt640ZeC5AyDhAhe7MGx6kxdbgbbqWFX_lkUgas9EH9WbTNEm6z_5-I1NB7xBeV4eBw</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>WAKAI, Yukiko</creator><creator>MATSUI, Junji</creator><creator>TSUTSUMI, Yasuo</creator><creator>NAKAGAWA, Shinsaku</creator><creator>OHSUGI, Yoshiyuki</creator><creator>MAYUMI, Tadanori</creator><creator>KOIZUMI, Keiichi</creator><creator>TSUNODA, Shin-Ichi</creator><creator>MAKIMOTO, Hiroo</creator><creator>OHIZUMI, Iwao</creator><creator>TANIGUCHI, Kenji</creator><creator>KAIHO, Shin-Ihi</creator><creator>SAITO, Hiroyuki</creator><creator>UTOGUCHI, Naoki</creator><general>Japanese Cancer Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20001201</creationdate><title>Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES23)</title><author>WAKAI, Yukiko ; MATSUI, Junji ; TSUTSUMI, Yasuo ; NAKAGAWA, Shinsaku ; OHSUGI, Yoshiyuki ; MAYUMI, Tadanori ; KOIZUMI, Keiichi ; TSUNODA, Shin-Ichi ; MAKIMOTO, Hiroo ; OHIZUMI, Iwao ; TANIGUCHI, Kenji ; KAIHO, Shin-Ihi ; SAITO, Hiroyuki ; UTOGUCHI, Naoki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j259t-3fccb9892b33ab04472e26c12c429114af67e9b8c853acc7cad64349667873413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibody Specificity</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Body Weight</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Endothelium, Vascular - immunology</topic><topic>Female</topic><topic>Fibrosarcoma - blood supply</topic><topic>Fibrosarcoma - drug therapy</topic><topic>Fibrosarcoma - radiotherapy</topic><topic>Hemorrhage</topic><topic>Immunoglobulin G</topic><topic>Iodine Radioisotopes - pharmacokinetics</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Necrosis</topic><topic>Pharmacology. Drug treatments</topic><topic>Radioimmunotherapy - methods</topic><topic>Rats</topic><topic>Tissue Distribution</topic><topic>Zinostatin - pharmacokinetics</topic><topic>Zinostatin - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>WAKAI, Yukiko</creatorcontrib><creatorcontrib>MATSUI, Junji</creatorcontrib><creatorcontrib>TSUTSUMI, Yasuo</creatorcontrib><creatorcontrib>NAKAGAWA, Shinsaku</creatorcontrib><creatorcontrib>OHSUGI, Yoshiyuki</creatorcontrib><creatorcontrib>MAYUMI, Tadanori</creatorcontrib><creatorcontrib>KOIZUMI, Keiichi</creatorcontrib><creatorcontrib>TSUNODA, Shin-Ichi</creatorcontrib><creatorcontrib>MAKIMOTO, Hiroo</creatorcontrib><creatorcontrib>OHIZUMI, Iwao</creatorcontrib><creatorcontrib>TANIGUCHI, Kenji</creatorcontrib><creatorcontrib>KAIHO, Shin-Ihi</creatorcontrib><creatorcontrib>SAITO, Hiroyuki</creatorcontrib><creatorcontrib>UTOGUCHI, Naoki</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of cancer research (Gann)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WAKAI, Yukiko</au><au>MATSUI, Junji</au><au>TSUTSUMI, Yasuo</au><au>NAKAGAWA, Shinsaku</au><au>OHSUGI, Yoshiyuki</au><au>MAYUMI, Tadanori</au><au>KOIZUMI, Keiichi</au><au>TSUNODA, Shin-Ichi</au><au>MAKIMOTO, Hiroo</au><au>OHIZUMI, Iwao</au><au>TANIGUCHI, Kenji</au><au>KAIHO, Shin-Ihi</au><au>SAITO, Hiroyuki</au><au>UTOGUCHI, Naoki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES23)</atitle><jtitle>Japanese journal of cancer research (Gann)</jtitle><addtitle>Jpn J Cancer Res</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>91</volume><issue>12</issue><spage>1319</spage><epage>1325</epage><pages>1319-1325</pages><issn>0910-5050</issn><eissn>1876-4673</eissn><coden>GANNA2</coden><abstract>Immunoconjugate targeting of solid tumors has not been routinely successful because the endo-thelial cells of blood vessels act as a physical barrier against the transport of macromolecules, such as antibodies. In the present study, we attempted to achieve tumor vascular targeting with an anti-tumor tissue endothelium-specific monoclonal antibody (TES-23). TES-23, an IgG1 monoclonal antibody raised against rat KMT-17 fibrosarcoma-derived endothelial cells, was covalently conjugated with neocarzinostatin (NCS) in a previous study. The TES-23-NCS conjugate induced tumor hemorrhagic necrosis, and showed marked anti-tumor effects against rat KMT-17 fibrosarcoma. This result prompted us to investigate whether this approach would be applicable to various other types of solid tumors. One hour after injection of (125)I-labeled TES-23 into BALB / c mice bearing Meth-A fibrosarcoma and Colon 26 adenocarcinoma, the tumor accumulation of TES-23 was greater than that of the control IgG. In the present study, we report the anti-tumor effects of this monoclonal antibody in mice bearing Meth-A fibrosarcoma. Mice treated with the immunoconjugate showed improved survival with no side effects. This result indicates that common antigens may be found in different kinds of tumor endothelial cells, and that TES-23 might recognize these antigens.</abstract><cop>Tokyo</cop><pub>Japanese Cancer Association</pub><pmid>11123432</pmid><doi>10.1111/j.1349-7006.2000.tb00920.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0910-5050 |
| ispartof | Japanese journal of cancer research (Gann), 2000-12, Vol.91 (12), p.1319-1325 |
| issn | 0910-5050 1876-4673 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72541090 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Antibody Specificity Antineoplastic agents Biological and medical sciences Body Weight Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Endothelium, Vascular - immunology Female Fibrosarcoma - blood supply Fibrosarcoma - drug therapy Fibrosarcoma - radiotherapy Hemorrhage Immunoglobulin G Iodine Radioisotopes - pharmacokinetics Iodine Radioisotopes - therapeutic use Medical sciences Mice Mice, Inbred BALB C Necrosis Pharmacology. Drug treatments Radioimmunotherapy - methods Rats Tissue Distribution Zinostatin - pharmacokinetics Zinostatin - therapeutic use |
| title | Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES23) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A37%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20cancer%20targeting%20using%20an%20anti-tumor%20tissue%20vascular%20endothelium-specific%20monoclonal%20antibody%20(TES23)&rft.jtitle=Japanese%20journal%20of%20cancer%20research%20(Gann)&rft.au=WAKAI,%20Yukiko&rft.date=2000-12-01&rft.volume=91&rft.issue=12&rft.spage=1319&rft.epage=1325&rft.pages=1319-1325&rft.issn=0910-5050&rft.eissn=1876-4673&rft.coden=GANNA2&rft_id=info:doi/10.1111/j.1349-7006.2000.tb00920.x&rft_dat=%3Cproquest_pubme%3E72541090%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72541090&rft_id=info:pmid/11123432&rfr_iscdi=true |